<DOC>
	<DOCNO>NCT01337349</DOCNO>
	<brief_summary>This prospective , double blind randomized clinical study evaluate Effects Pentoxifylline leave ventricular systolic function index circulate biomarkers patient chronic congestive heart failure . A study focus Africa consistently show marked beneficial effect pentoxifylline improvement leave ventricular size systolic function along marked decrease biomarkers heart failure apoptosis marker top standard CHF therapy . Furthermore pentoxifylline show negligible effect heart rate , blood pressure study . Limitations study largely single center originate African subcontinent never test North American population , particularly Caucasians . Despite major advance medical therapy congestive heart failure , still one leading cause morbidity mortality North America . Most medication test improvement Ejection Fraction exception Beta-Blockers Ace-Inhibitors associate worsen mortality . Pentoxifylline medication negligible effect myocardial oxygen consumption , yet promise effect inflammatory marker see CHF possibility improvement LV systolic function symptomology may prove useful addition CHF patient . This would prove especially useful , particularly associate major side effect .</brief_summary>
	<brief_title>Effects Pentoxiphylline Left Ventricular ( LV ) Systolic Function Indices Circulating Biomarkers Patients With Chronic Congestive Heart Failure ( CHF )</brief_title>
	<detailed_description>Patients meet inclusion criterion baseline physical exam , Heart Failure status assessment base Kansas City Heart Failure Questionnaire , EF assessment base SPECT MUGA , cardiopulmonary exam evaluate Vo2 max assessment leave ventricular end diastolic systolic dimension base 2D echo lab draw assess circulate biomarkers . Patients randomize control population receive placebo medication vs. study population receive pentoxiphylline 400mg three time daily 6 month . Patients also one three month clinic visit assess potential change symptom assess medication compliance . Patients 6 month follow-up repeat physical exam , Heart Failure status assessment base Kansas City Heart Failure Questionnaire , EF assessment base SPECT MUGA , cardiopulmonary exam ass Vo2 Max assessment leave ventricular end diastolic systolic dimension base 2D echo lab draw assess circulate biomarkers .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<criteria>1 . Nonischemic ischemic class IIIII heart failure patient maximally tolerate evidence base medication . ( i.e . BB ( coreg , toprol , bisoprolol ) , ACEI/ARBS , Diuretics , +/ aldactone , digoxin ) . 2 . Patients also expect survival great 6 month , include comorbidities . 3 . Sinus Rhythm 4 . Age &gt; 18 5 . LVEF &lt; 40 % assess ( SPECT MUGA , ECHO ) . 1 . Class I Class IV heart failure patient , patient newly diagnose currently traditional evidence base medication . 2 . Patients BiVICD placement . 3 . Patients decompensate class IV heart failure study period require inotropes , LVAD , upgrade BiVICD , report potential treatment failure take study . 4 . Patients whose clinical condition cardiomyopathy could influence inflammatory biomarkers . ( i.e . Connective Tissue disorder , HIV ) 5 . Pregnancy 6 . Severe exercise induce malignant ventricular arrhythmia 7 . Any systemic process cardiomyopathy would lead survival &lt; 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Pentoxifylline</keyword>
	<keyword>Chronic Congestive Heart Failure</keyword>
	<keyword>Left Systolic Function</keyword>
	<keyword>Biomarkers</keyword>
</DOC>